Bristol-Myers Squibb Company · NYSE:BMY
Bristol-Myers Squibb — UBS Healthcare Conference 2015
12 slides from Bristol-Myers Squibb's conference presentation, May 20, 2015
Slide 1: UBS Healthcare Conference
UBS Healthcare Conference Charlie Bancroft Executive Vice President, Chief Financial Officer May 20, 2015 NOT FOR PRODUCT PROMOTIONAL USE
Slide 2: Forward-Looking Information
Forward-Looking Information This presentation contains statements about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from
Slide 3: Our Strategic Foundation
Our Strategic Foundation Best of Best of BIOTECH PHARMA Diversified Specialty BioPharma I N N O VAT E I N T E G R AT E IMPROVE People helping patients in their fight against serious disease NOT FOR PRODUCT PROMOTIONAL USE 3
Slide 4: Keys to Future Growth
Keys to Future Growth Invest for long-term growth… balance short-term results Realize the potential of Immuno-Oncology Commercial execution of inline growth products Diversify for long-term sustainable growth Balanced approach to capital allocation NOT FOR PRODUCT PROMOTIONAL USE 4
Slide 5: Q1 2015: Strong Sales Performance vs. Prior Year
Q1 2015: Strong Sales Performance vs. Prior Year Q1 sales of $4B, up 6% vs. prior year $264 M >100 % 10 % 10 % 20 % $ 40 M NOT FOR PRODUCT PROMOTIONAL USE 5
Slide 6: Our R&D Focus
Our R&D Focus DISEASE AREA FOCUS Immuno- Oncology Immunoscience Cardiovascular Oncology Virology Fibrotic Genetically Diseases Defined Diseases Small Molecules Biologics Gene Therapy MODALITIES Millamolecules Antibody Drug Conjugates NOT FOR PRODUCT PROMOTIONAL USE 6
Slide 7: ASCO 2015: Key I-O Data
ASCO 2015: Key I-O Data • Results from Phase 3 Nivolumab studies – Squamous NSCLC (-017) – Non-squamous NSCLC (-057) – Mono Nivo and combo w/ Ipi in melanoma (-067) • Refractory multiple myeloma, elotuzumab (Eloquent 2) • Long term follow-up in renal cell carcinoma (-010) • New tumors: SCLC, Gliobla
Slide 8: Capital Allocation: A Balanced Approach
Capital Allocation: A Balanced Approach • Continue to be in a solid financial position – Strong balance sheet – Business development remains a top priority – Dividend commitment 6th consecutive annual increase NOT FOR PRODUCT PROMOTIONAL USE 8
Slide 9: Business Development: Core to Our Strategy
Business Development: Core to Our Strategy Licensing Acquisition Partnerships Strategically, Scientifically & Financially Aligned NOT FOR PRODUCT PROMOTIONAL USE 9
Slide 10: Enhancing the Portfolio through Business Development
Enhancing the Portfolio through Business Development Immuno-Oncology Oncology Specialty uniQure NOT FOR PRODUCT PROMOTIONAL USE 10
Slide 11: Confident in Our Future
Confident in Our Future Realizing the potential of I-O Strong performance from key product launches Diversified specialty pipeline to fuel growth Disciplined capital allocation Positioned for long-term success NOT FOR PRODUCT PROMOTIONAL USE 11 11
Slide 12: UBS Healthcare Conference
UBS Healthcare Conference Charlie Bancroft Executive Vice President, Chief Financial Officer May 20, 2015 NOT FOR PRODUCT PROMOTIONAL USE
Bristol-Myers Squibb Company — UBS Healthcare Conference 2015 on 6ix